Becton, Dickinson and Company (BDX) Expected to Announce Quarterly Earnings on Thursday

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) is projected to issue its Q3 2025 quarterly earnings data before the market opens on Thursday, August 7th. Analysts expect Becton, Dickinson and Company to post earnings of $3.44 per share and revenue of $5.50 billion for the quarter.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last posted its quarterly earnings results on Thursday, May 1st. The medical instruments supplier reported $3.35 EPS for the quarter, beating the consensus estimate of $3.28 by $0.07. The business had revenue of $5.27 billion during the quarter, compared to analyst estimates of $5.35 billion. Becton, Dickinson and Company had a net margin of 7.28% and a return on equity of 15.99%. The company's quarterly revenue was up 4.5% on a year-over-year basis. During the same period in the previous year, the business posted $3.17 EPS. On average, analysts expect Becton, Dickinson and Company to post $14 EPS for the current fiscal year and $16 EPS for the next fiscal year.

Becton, Dickinson and Company Stock Performance

BDX traded down $2.06 on Friday, hitting $176.19. 4,688,991 shares of the company's stock were exchanged, compared to its average volume of 2,645,222. The company has a current ratio of 1.13, a quick ratio of 0.64 and a debt-to-equity ratio of 0.70. The stock has a fifty day moving average of $174.83 and a two-hundred day moving average of $201.28. Becton, Dickinson and Company has a twelve month low of $163.33 and a twelve month high of $251.99. The firm has a market cap of $50.50 billion, a PE ratio of 33.62, a P/E/G ratio of 1.37 and a beta of 0.25.

Becton, Dickinson and Company Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 30th. Investors of record on Monday, September 8th will be given a dividend of $1.04 per share. The ex-dividend date is Monday, September 8th. This represents a $4.16 dividend on an annualized basis and a yield of 2.4%. Becton, Dickinson and Company's payout ratio is currently 79.39%.

Insider Buying and Selling

In other Becton, Dickinson and Company news, EVP David Shan sold 1,166 shares of the company's stock in a transaction dated Monday, June 2nd. The shares were sold at an average price of $171.19, for a total value of $199,607.54. Following the completion of the sale, the executive vice president directly owned 4,575 shares of the company's stock, valued at approximately $783,194.25. This represents a 20.31% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Michael David Garrison sold 1,185 shares of Becton, Dickinson and Company stock in a transaction on Friday, July 18th. The stock was sold at an average price of $180.29, for a total value of $213,643.65. Following the completion of the transaction, the executive vice president owned 4,887 shares in the company, valued at $881,077.23. The trade was a 19.52% decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 0.36% of the company's stock.

Institutional Investors Weigh In On Becton, Dickinson and Company

An institutional investor recently raised its position in Becton, Dickinson and Company stock. Empowered Funds LLC raised its position in Becton, Dickinson and Company (NYSE:BDX - Free Report) by 20.4% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 7,977 shares of the medical instruments supplier's stock after purchasing an additional 1,354 shares during the quarter. Empowered Funds LLC's holdings in Becton, Dickinson and Company were worth $1,827,000 at the end of the most recent quarter. 86.97% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on the company. Bank of America lowered Becton, Dickinson and Company from a "buy" rating to a "neutral" rating and set a $190.00 target price on the stock. in a research report on Thursday, May 1st. Piper Sandler downgraded shares of Becton, Dickinson and Company from an "overweight" rating to a "neutral" rating and cut their price objective for the company from $260.00 to $185.00 in a research report on Friday, May 2nd. Barclays reduced their target price on shares of Becton, Dickinson and Company from $261.00 to $241.00 and set an "overweight" rating for the company in a research note on Tuesday, June 3rd. Raymond James Financial lowered shares of Becton, Dickinson and Company from an "outperform" rating to a "market perform" rating in a research note on Friday, May 2nd. Finally, Wells Fargo & Company downgraded Becton, Dickinson and Company from an "overweight" rating to an "equal weight" rating in a research report on Thursday, May 1st. Eight research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat.com, Becton, Dickinson and Company currently has an average rating of "Hold" and a consensus target price of $219.22.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.